Немецкий медицинский журнал Немецкий медицинский журнал

Coronary Stents
THE JOURNAL OF MEDICINE FOR THE WORLDWIDE MED COMMUNITY
Коронарные стенты
Risk Factors for Stent Thrombosis
Patient factors
Acute coronary syndrome
Diabetes mellitus
Renal failure
Imparied left ventricular function
Discontinuation of dual antiplatelet therapy
Clopidogrel Non-responder
Advanced age
data will be expected from the
randomized PROTECT trial of
8,800 „all-comers“ patients assigned
to treatment with either
ZES or SES [27].
2. The Xience-V EES
The Xience-V EES, receiving
EMEA and FDA approval in
January 2006 and July 2008,
respectively, is based on a
CoCr Multi-Link Vision BMS
platform (Abbott Vascular,
California) coated by a formulation
of everolimus, poly-n-butyl
methacrylate (PBMA) and a
permanent, but biocompatible
co-polymer poly-vinylidene
fluoride-co-hexafluoropropylene
(PVDF-HFP). The drug-polymer
coating is applied to the entire
stent surface with a standard
concentration of 100μg/cm 2 of
stent surface area and is designed
to release approximately
80% of the total dose within
30 days of stent placement,
with nearly all drug released
within 4 months [28].
An experimental study in rabbit
iliac arteries revealed more
rapid and complete endothelialization
with EES than with
SES, PES or ZES. While reendothelialization
of struts at
14 days was variable among
comparator stents, significantly
greater coverage was seen
with EES (66±27.5%), followed
by ZES (30.2%±14.2%),
PES (26.8%±15.8%), and SES
Lesion characteristics
Procedural factors
Device factors
Table 1: Predictors for stent thrombosis
Таблица 1: Предвестники тромбоза стента
(6.4%±4.2%) (p